Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytoprotection: concepts and challenges

F M Muggia1

  • 1University of Southern California, Norris Canter Center, Los Angeles 90033.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.

Gynecologic oncology·2024
Same author

BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Brain metastases from choriocarcinoma: two patients illustrating key management issues.

Journal of chemotherapy (Florence, Italy)·2008
Same author

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2005
Same author

Platinums: extending their therapeutic spectrum.

Journal of chemotherapy (Florence, Italy)·2005
Same author

'Retarded pharmaceuticals' assuming a clinical role.

Onkologie·2004
Same journal

Central venous access device-associated complication costs in paediatric cancer care.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same journal

Self-reported peripheral neuropathic symptoms in long-term adolescent and young adult (AYA) cancer survivors: results of the SURVAYA study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same journal

Meaning-centered psychotherapy for Chinese caregivers of patients with advanced cancer: Cultural and linguistic adaptation.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same journal

Nonpharmacological interventions for preventing delirium in adult patients with cancer: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same journal

Mental illness and health literacy in people with cancer: the Australian National Health Survey analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same journal

User profiles of young breast cancer survivors on Chinese social media: machine learning-based text mining analysis study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
See all related articles

Clinical trials explored toxicity protectors to reduce chemotherapy side effects and enhance antitumor activity. These complex studies, despite challenges, offer tangible clinical benefits and improved understanding of cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Clinical trials have investigated toxicity protectors, including cytoprotective and chemoprotective agents, over the past decade.
  • These agents aim to mitigate dose-limiting toxicities associated with cancer therapies.

Purpose of the Study:

  • To assess the complexity and outcomes of clinical trials involving toxicity protectors.
  • To understand the manipulation of drug actions for enhanced antitumor activity or reduced toxicity.

Main Methods:

  • Clinical trials designed to include sufficient dose-limiting events.
  • Assessment of both toxicity and antitumor effects to evaluate protection efficacy.

Main Results:

  • Examples include dexrazoxane (ICRF-187) for doxorubicin cardiotoxicity and amifostine for myelosuppression from platinum and alkylating agents.

Related Experiment Videos

  • Studies have yielded considerable understanding of therapeutic issues and demonstrated clinical benefit in specific situations.

    • Conclusions:

    • Despite developmental challenges, toxicity protectors have led to significant insights in cancer therapy.
    • These agents offer tangible clinical benefits and improved patient outcomes in select cases.